Research summary

The main aim of my research is to overcome the barriers to translational medicine in neurodegenerative diseases by identifying the earliest pathological pathways activated in motor neuron disease in order to define the most therapeutically tractable areas for drug therapy and to apply these findings to clinical studies in patients. In particular, we aim to understand why ubiquitously expressed proteins involved in RNA processing and trafficking (SMN, FUS and TDP-43) are critically important for motor neuron integrity. Our research encompasses basic molecular studies in model systems in the laboratory and tissue from patients. A major biomarkers study in ALS (BioMOx), led by Dr Martin Turner is developing ways of tracking disease using imaging and proteomics, but is also providing important new insights into basic disease mechanisms.

Kevin Talbot qualified in medicine (MB BS) with Distinction from the University of London and trained in Neurology in London and Oxford. He joined the laboratory of Professor Kay Davies in 1995 to work on the childhood motor neuron disorder spinal muscular atrophy, which has remained a major focus of his research ever since. From 1998-2001 he was Clinical Lecturer in Neurology and from 2001-2006 held an MRC Clinician Scientist Fellowship. He leads a multidisciplinary team providing a clinical service for patients with motor neuron disease from all over the South of England. In 2010 he became Professor of Motor Neuron Biology.